Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial

Conclusions: RIVER-PCI is a novel, large-scale, international, randomized, double-blind, placebo-controlled clinical trial evaluating the role of ranolazine in the long-term medical management of patients with ICR post-PCI.

Source: American Heart Journal - October 18, 2013 Category: Cardiology Authors: Giora Weisz, Ramin Farzaneh-Far, Ori Ben-Yehuda, Bernard DeBruyne, Gilles Montalescot, Amir Lerman, Ehtisham Mahmud, Karen P. Alexander, E. Magnus Ohman, Harvey D. White, Ann Olmsted, Gennyne A. Walker, Gregg W. Stone Tags: Trial Design Source Type: research